Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus

Published:2020-12 Issue:6 Volume:13 Page:
ISSN:2574-8300
Container-title:Circulation: Genomic and Precision Medicine
language:en
Short-container-title:Circ: Genomic and Precision Medicine

Author:

van Zuydam Natalie R.¹²³^ORCID,Ladenvall Claes⁴^ORCID,Voight Benjamin F.⁵⁶⁷^ORCID,Strawbridge Rona J.⁸^ORCID,Fernandez-Tajes Juan³^ORCID,Rayner N. William²³⁹^ORCID,Robertson Neil R.²³,Mahajan Anubha²³,Vlachopoulou Efthymia¹⁰,Goel Anuj³¹¹^ORCID,Kleber Marcus E.,Nelson Christopher P.¹²¹³,Kwee Lydia Coulter¹⁴^ORCID,Esko Tõnu¹⁵^ORCID,Mihailov Evelin¹⁵,Mägi Reedik¹⁵^ORCID,Milani Lili¹⁵^ORCID,Fischer Krista¹⁵^ORCID,Kanoni Stavroula¹⁶¹⁷¹⁸¹⁹²⁰^ORCID,Kumar Jitender²¹²²,Song Ci²¹²³²⁴²⁵,Hartiala Jaana A.²⁶^ORCID,Pedersen Nancy L.²⁷^ORCID,Perola Markus²⁸¹⁵²⁹^ORCID,Gieger Christian³⁰³¹³²,Peters Annette³⁰³²³³^ORCID,Qu Liming³⁴³⁵³⁶,Willems Sara M.³⁷^ORCID,Doney Alex S.F.³⁸,Morris Andrew D.³⁹⁴⁰,Zheng Yan³⁵⁴¹^ORCID,Sesti Giorgio⁴²^ORCID,Hu Frank B.³⁵⁴³⁴⁴^ORCID,Qi Lu³⁴³⁵³⁶^ORCID,Laakso Markku⁴⁵⁴⁶^ORCID,Thorsteinsdottir Unnur⁴⁷,Grallert Harald³⁰³¹⁴⁸⁴⁹,van Duijn Cornelia³⁷^ORCID,Reilly Muredach P.³⁴^ORCID,Ingelsson Erik²¹⁵⁰⁵¹⁵²,Deloukas Panos¹⁷⁵³^ORCID,Kathiresan Sek¹⁶¹⁷¹⁸¹⁹²⁰^ORCID,Metspalu Andres¹⁵⁵⁴^ORCID,Shah Svati H.⁵⁵¹⁴,Sinisalo Juha⁵⁶^ORCID,Salomaa Veikko²⁹^ORCID,Hamsten Anders⁸,Samani Nilesh J.¹²¹³^ORCID,März Winfried⁵⁷⁵⁸,Hazen Stanley L.⁵⁹^ORCID,Watkins Hugh³¹¹^ORCID,Saleheen Danish⁶⁰⁶¹,Morris Andrew P.³⁶²⁶³,Colhoun Helen M.⁶⁴⁶⁵^ORCID,Groop Leif⁴,McCarthy Mark I.²³⁶⁶^ORCID,Palmer Colin N.A.¹^ORCID,Danesh John,Erdmann Jeanette,Gu Dongfeng,Kooner Jaspal S.,Roberts Robert,Schunkert Heribert,Assimes Themistocles L.,Blankenberg Stefan,Boehm Bernhard O.,Chambers John C.,Clarke Robert,Collins Rory,Dedoussis George,Franks Paul W.,Hovingh G. Kees,Kim Bong-Jo,Lehtimäki Terho,McPherson Ruth,Nieminen Markku S,O’Donnell Christopher,Ripatti Samuli,Sandhu Manjinder S,Schreiber Stefan,Siegbahn Agneta,Willer Cristen J.,Zalloua Pierre A.,Mark Michael,Kanninen Timo,Thorand Barbara,Remuzzi Giuseppe,Dunger David,Shore Angela,Smith Ulf,Groop Per-Henrik^ORCID,Ylä-Herttuala Seppo,Cobelli Claudio,Bellazzi Riccardo,Ferrannini Ele,Patrono Carlo,Nuutila Pirjo,McKeague Paul,Steckel-Hamann Birgit,Gan Li-ming,Nogoceke Everson,Tortoli Piero,Jablonka Bernd,Brosnan Mary-Julia

Affiliation:

1. Pat Macpherson Center for Pharmacogenetics & Pharmacogenomics, Cardiovascular & Diabetes Medicine (N.R.v.Z., C.N.A.P.), School of Medicine, University of Dundee.

2. Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine (N.R.v.Z., N.W.R., N.R.R., A. Mahajan, M.I.Mc), University of Oxford, United Kingdom.

3. Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.

4. Department of Clinical Sciences, Diabetes & Endocrinology, Lund University Diabetes Center, Malmö, Sweden (C.L., L.G.).

5. Department of Systems Pharmacology & Translational Therapeutics (B.F.V.)

6. Department of Genetics (B.F.V.)

7. Institute for Translational Medicine & Therapeutics (B.F.V.)

8. Cardiovascular Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden (R.J.S., A.H.).

9. Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom (N.W.R.).

10. Transplantation Laboratory, Haartman Institute (E.V.), University of Helsinki, Helsinki, Finland.

11. Division of Cardiovascular Medicine (A.G., H.W.), University of Oxford, United Kingdom.

12. Department of Cardiovascular Sciences, University of Leicester (C.P.N., N.J.S.).

13. NIHR Leicester Biomedical Research Center, Glenfield Hospital, Leicester, United Kingdom (C.P.N., N.J.S.).

14. Duke Molecular Physiology Institute, Duke University, Durham, NC (L.C.K., S.H.S.).

15. Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.

16. Center for Genomic Health (S.K.), Queen Mary University of London, London, United Kingdom.

17. William Harvey Research Institute, Barts & the London Medical School (S.K., P.D.), Queen Mary University of London, London, United Kingdom.

18. Broad Institute of MIT & Harvard, Cambridge (S.K.).

19. Cardiology Division, Center for Human Genetic Research (S.K.), Massachusetts General Hospital & Harvard Medical School, Boston, MA.

20. Cardiovascular Research Center (S.K.), Massachusetts General Hospital & Harvard Medical School, Boston, MA.

21. Department of Medical Sciences, Molecular Epidemiology & Science for Life Laboratory (J.K., C.S., E.I.)

22. Center for Computational Biology & Bioinformatics, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, India (J.K.).

23. Department of Immunology, Genetics and Pathology, Medical Genetics & Genomics, Uppsala University, Uppsala, Sweden (C.S.).

24. Framingham Heart Study (C.S.).

25. Population Sciences Branch, National Heart, Lung & Blood Institute, National Institute of Health, Framingham, MA (C.S.).

26. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (J.A.H.).

27. Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden (N.L.P.).

28. Research Program for Clinical & Molecular Metabolism, Faculty of Medicine (M.P.), University of Helsinki, Helsinki, Finland. Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

29. National Institute for Health and Welfare, Helsinki, Finland (M.P., V.S.).

30. German Center for Diabetes Research (DZD), München-Neuherberg (C.G., A.P., H.G.).

31. Clinical Cooperation Group Type 2 Diabetes (C.G., H.G.), Helmholtz Zentrum München, Neuherberg, Germany.

32. German Research Center for Environmental Health & Institute of Genetic Epidemiology (C.G., A.P.), Helmholtz Zentrum München, Neuherberg, Germany.

33. DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (A.P.).

34. Cardiovascular Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA (L.Q., M.P.R.).

35. Department of Nutrition (Y.Z., F.B.H., L.Q.)

36. Department of Epidemiology, School of Public Health & Tropical Medicine, Tulane University, New Orleans, LA (L.Q.).

37. Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands (S.M.W., C.v.D.).

38. Division of Molecular & Clinical Medicine (A.S.F.D.), School of Medicine, University of Dundee.

39. The Usher Institute of Population Health Sciences & Informatics (A.D.M.), University of Edinburgh, Edinburgh, U.K.

40. Health Data Research UK, London, United Kingdom (A.D.M.).

41. Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China (Y.Z.).

42. University “Magna Graecia” of Catanzaro, Italy (G.S.).

43. Department of Epidemiology, Harvard School of Public Health, Boston, MA (F.B.H.).

44. Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA (F.B.H.).

45. Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland (M.L.).

46. Kuopio University Hospital, Finland (M.L.).

47. Faculty of Medicine, University of Iceland. deCODE Genetics, Reykjavik, Iceland (U.T.).

48. Research Unit of Molecular Epidemiology, Institute of Epidemiology (H.G.), Helmholtz Zentrum München, Neuherberg, Germany.

49. Clinical Cooperation Group Nutrigenomics & Type 2 Diabetes (H.G.), Helmholtz Zentrum München, Neuherberg, Germany.

50. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine (E.I.).

51. Stanford Cardiovascular Institute (E.I.)

52. Stanford Diabetes Research Center, Stanford University, Stanford, CA (E.I.).

53. Princess Al-Jawhara Al-Brahim Center of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia (P.D.).

54. Institute of Cell & Molecular Biology (A. Metspalu), University of Tartu, Tartu, Estonia.

55. Division of Cardiology, Department of Medicine, Duke University Medical Center (S.H.S.)

56. Heart & Lung Center, Helsinki University Hospital (J.S.) and Institute for Molecular Medicine Finland (FIMM), Helsinki University, Helsinki, Finland.

57. Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany (W.M.).

58. Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Graz, Austria (W.M.).

59. Lerner Research Institute, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH (S.L.H.).

60. Department of Biostatistics & Epidemiology, University of Pennsylvania, Philadelphia, PA (D.S.).

61. Center for Non-Communicable Diseases, Karachi, Pakistan (D.S.).

62. Department of Biostatistics, University of Liverpool, Liverpool, U.K. (A.P.M.).

63. Division of Musculoskeletal & Dermatological Sciences, University of Manchester, Manchester, U.K. (A.P.M.).

64. MRC Institute of Genetics & Molecular Medicine (H.M.C.), University of Edinburgh, Edinburgh, U.K.

65. Public Health, NHS Fife, Kirkcaldy, Fife, U.K. (H.M.C.).

66. Oxford NIHR Biomedical Research Center, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom (M.I.Mc).

Abstract

Background: Coronary artery disease (CAD) is accelerated in subjects with type 2 diabetes mellitus (T2D). Methods: To test whether this reflects differential genetic influences on CAD risk in subjects with T2D, we performed a systematic assessment of genetic overlap between CAD and T2D in 66 643 subjects (27 708 with CAD and 24 259 with T2D). Variants showing apparent association with CAD in stratified analyses or evidence of interaction were evaluated in a further 117 787 subjects (16 694 with CAD and 11 537 with T2D). Results: None of the previously characterized CAD loci was found to have specific effects on CAD in T2D individuals, and a genome-wide interaction analysis found no new variants for CAD that could be considered T2D specific. When we considered the overall genetic correlations between CAD and its risk factors, we found no substantial differences in these relationships by T2D background. Conclusions: This study found no evidence that the genetic architecture of CAD differs in those with T2D compared with those without T2D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference32 articles.

1. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years

2. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects.

3. Diabetes mellitus

4. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

5. A decade of genome-wide association studies for coronary artery disease: the challenges ahead.;Erdmann J;Cardiovasc Res,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coronary artery disease patients with rs7904519 (TCF7L2) are at a persistent risk of type 2 diabetes;Diabetes Research and Clinical Practice;2024-01

2. Type 2 Diabetes Modifies the Association of CAD Genomic Risk Variants With Subclinical Atherosclerosis;Circulation: Genomic and Precision Medicine;2023-12

3. Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes;Diabetes Care;2023-05-01

4. Genetics of Coronary Artery Disease in Diabetes Mellitus;Diabetes and Cardiovascular Disease;2023

5. Genetics of macrovascular complications in type 2 diabetes;World Journal of Diabetes;2021-08-15